Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Excision BioTherapeutics

Main focus: Gene editing for the treatment of viral infections

Company stage: Pre-clinical

Diseases: HIV-1 infection/AIDS, progressive multifocal leukoencephalopathy (PML), Herpes simplex virus (HSV) infection, hepatitis B virus (HBV) infection

Genome editing tool: CRISPR-Cas9, CRISPR-CasX

Funding stage: Private

Location: San Francisco, CA, USA



Excsision BioTherapeutics is a start-up gene-editing company focused on curing viral infections with CRISPR. The company has developed a proprietary technolegy where dual gRNAs excise large sections of viral DNA, eliminating viral escape and reproduction. Its lead programme, EBT-101, is being developed to destroy the human immunodeficiency virus (HIV), to ultimately cure infection by the virus. Other programmes focus on eliminating viruses such as herpex simplex virus and hepatitis B virus.


HashtagExcision BioTherapeutics

Company: Excision BioTherapeutics
Search CRISPR Medicine